Spyre Therapeutics (SYRE) Free Cash Flow (2015 - 2026)
Spyre Therapeutics (SYRE) posted Free Cash Flow of -$57.4 million for Q1 2026, down 28.7% on a QoQ basis from -$44.6 million in Q4 2025, and down 39.95% year-over-year from -$95.5 million in Q1 2025.
Spyre Therapeutics (SYRE) Free Cash Flow (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Free Cash Flow history runs 12 years deep, the most recent figure standing at -$57.4 million for Q1 2026.
- Quarterly Free Cash Flow fell 39.95% year-over-year to -$57.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$185.6 million (down 9.28% YoY) and the FY2025 annual result came in at -$169.3 million, down 7.52% from the prior year.
- Free Cash Flow was -$57.4 million for Q1 2026 at Spyre Therapeutics, down from -$44.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$15.1 million in Q3 2022 and bottomed at -$62.2 million in Q2 2024.
- A 5-year average of -$33.1 million and a median of -$31.0 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 1107.46% — and 2023, when it jumped 32.95%.
- Spyre Therapeutics' Free Cash Flow stood at -$18.1 million in 2022, then plunged by 71.09% to -$31.0 million in 2023, then dropped by 19.86% to -$37.2 million in 2024, then slipped by 19.84% to -$44.6 million in 2025, then retreated by 28.7% to -$57.4 million in 2026.
- Business Quant data shows SYRE's Free Cash Flow at -$57.4 million in Q1 2026, -$44.6 million in Q4 2025, and -$37.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | -57.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.37 Mn |
| Mar 31, 2026 | -57.37 Mn |
| Dec 31, 2025 | -44.58 Mn |
| Dec 31, 2025 | -44.58 Mn |
| Sep 30, 2025 | -37.12 Mn |
| Sep 30, 2025 | -37.12 Mn |
| Jun 30, 2025 | -46.56 Mn |
| Jun 30, 2025 | -46.56 Mn |
| Mar 31, 2025 | -40.99 Mn |
| Mar 31, 2025 | -40.99 Mn |
| Dec 31, 2024 | -37.20 Mn |
| Dec 31, 2024 | -37.20 Mn |
| Sep 30, 2024 | -29.42 Mn |
| Sep 30, 2024 | -29.42 Mn |
| Jun 30, 2024 | -62.25 Mn |
| Jun 30, 2024 | -62.25 Mn |
| Mar 31, 2024 | -28.54 Mn |
| Mar 31, 2024 | -28.54 Mn |
| Dec 31, 2023 | -31.04 Mn |
| Dec 31, 2023 | -31.04 Mn |